You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,664,215


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,664,215
Title:Ocular allergy treatments with alcaftadine
Abstract: Compositions, kits, and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof containing alcaftadine or a pharmaceutically acceptable salt thereof.
Inventor(s): Ingerman; Avner (Scarsdale, NY), Janssens; Frans (Bonheiden, BE), Megens; Anton (Beerse, BE), Abelson; Mark B. (Andover, MA)
Assignee: Vistakon Pharmaceuticals, LLC (Jacksonville, FL)
Application Number:11/690,954
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,664,215
Patent Claims: 1. A method of treating a clinical symptom of ocular allergy, comprising administering once daily to the eye of a human patient with said clinical symptom of ocular allergy an ophthalmic composition comprising alcaftadine, its pharmaceutically acceptable salts, or mixtures thereof.

2. The method of claim 1 wherein the ocular allergy is allergic conjunctivitis.

3. The method of claim 1 wherein the ophthalmic composition comprises from about 0.2% to about 0.35% by weight of alcaftadine.

4. A method of preventing ocular itching in a human patient exposed to a conjunctival allergen, comprising administering once daily to the eye of said human patient an ophthalmic composition comprising alcaftadine, its pharmaceutically acceptable salts, or mixtures thereof, wherein prevention comprises inhibiting said ocular itching compared to a non-treated patient.

5. The method of claim 4 wherein the ophthalmic composition comprises from about 0.2% to about 0.35% by weight of alcaftadine.

6. The method of claim 4 wherein the ophthalmic composition comprises about 0.25% by weight of alcaftadine.

7. The method of claim 1 wherein the ophthalmic composition comprises about 0.25% by weight of alcaftadine.

8. The method according to claim 4 wherein said ophthalmic composition comprising alcaftadine is administered prior to exposure to a conjunctival allergen.

9. The method according to claim 4 wherein said ophthalmic composition comprising alcaftadine is administered after exposure to a conjunctival allergen.

10. The method according to claim 4 further comprising preventing conjunctival redness, chemosis, and lid edema in said human patient exposed to said conjunctival allergen wherein prevention comprises inhibiting said conjunctival redness, chemosis, and lid edema.

11. A method of preventing conjunctival redness, chemosis, and lid edema for a period exceeding 16 hours in a human patient exposed to a conjunctival allergen comprising administering once daily to the eye of said human patient an ophthalmic composition comprising alcaftadine, its pharmaceutically acceptable salts, or mixtures thereof, wherein prevention comprises inhibiting said wherein prevention comprises inhibiting said conjunctival redness, chemosis, and lid edema compared to a non-treated patient.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.